ADMA Biologics 2025 Q3 Earnings Record Net Income Marks 14-Year High

ADMA Biologics (ADMA) reported fiscal 2025 Q3 earnings on Nov 5, 2025, with results in line with expectations and raised revenue guidance for the year. , driven by strong performance in its core manufacturing segment. Management also reaffirmed confidence in long-term margin expansion and updated investors on strategic milestones, including FDA approvals and product development progress.

Revenue

, while Plasma Collection Centers reported no revenue during the period. , . The segment performance underscored the company’s vertical integration and focus on plasma-derived biologics.

Earnings/Net Income

, matching the prior year’s Q3. , , marking the highest Q3 net income in 14 years. The EPS consistency and net income growth reflect disciplined cost management and operational efficiencies.

Price Action

Following the earnings release, , . Month-to-date, , indicating mixed short-term investor sentiment despite strong financial results.

Post-Earnings Price Action Review

. However, the subsequent weekly decline suggested some profit-taking or skepticism about near-term execution risks. Month-to-date, , including yield-enhanced production and ASCENIV demand. The price action reflects a balance between short-term volatility and long-term optimism about the company’s vertical integration and product pipeline.

CEO Commentary

, profitable growth, , constructive 2026 payer negotiations, and operational efficiency initiatives, including share repurchases and capital deployment. , durable demand for plasma-derived biologics, and long-term stockholder value creation.

Guidance

. . . , driven by margin expansion, demand, and . Guidance excludes SG-001 and capacity expansion upside.

Additional News

, , . The company also highlighted progress on its SG-001 program, . Additionally, , underscoring confidence in long-term growth.